Anti-phospho-PARK2 (Ser101) antibody
| 英文名称 | phospho-PARK2 (Ser101) |
| 中文名称 | 磷酸化帕金蛋白抗体 |
| 别 名 | Parkin (phospho Ser101); Parkin (phospho S101); p-Parkin (phospho S101); PARK2(phospho S101); AR JP; E3 ubiquitin protein ligase parkin; FRA6E; LPRS 2; LPRS2; PARK 2; PARK2; Parkinson disease (autosomal recessive juvenile) 2; Parkinson disease protein 2; Parkinson juvenile disease protein 2; PDJ; PRKN 2; PRKN; PRKN2; Ubiquitin E3 ligase PRKN. |
DATASHEET
Host:Rabbit
Target Protein:phospho-PARK2 (Ser101)
IR:Immunogen Range:PQ(p-S)LT
Clonality:Polyclonal
Isotype:IgG
Entrez Gene:5071
Swiss Prot:O60260
Source:KLH conjugated Synthesised phosphopeptide derived from human PARK2 around the phosphorylation site of Ser101:PQ(p-S)LT
Purification:affinity purified by Protein A
Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background:Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions). Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome.
Size:100ul
Concentration:1mg/ml
Applications:WB(1:500-2000)
ELISA(1:5000-10000)
Cross Reactive Species:Human
.
For research use only. Not intended for diagnostic or therapeutic use.
好评度